You are here

  • Home
  • Archive
  • Volume 77, Issue 7
  • Response to: ‘Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms’ by Reginster et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms’ by Reginster et al
  1. Jos Runhaar1,
  2. Rianne M Rozendaal1,
  3. Marienke van Middelkoop1,
  4. Hans J W Bijlsma2,
  5. Michael Doherty3,
  6. Krysia S Dziedzic4,
  7. L Stefan Lohmander5,
  8. Timothy McAlindon6,
  9. Weiya Zhang3,
  10. Sita Bierma Zeinstra1,7
  1. 1 Department of General Practice, Erasmus University Medical Center Rotterdam, Rotterdam, Zuid-Holland, Netherlands
  2. 2 Department of Rheumatology, UMC Utrecht, Utrecht, Netherlands
  3. 3 Department of Rheumatology, University of Nottingham, Nottingham, UK
  4. 4 Department of Primary Care & Health Services, Keele University, Staffordshire, UK
  5. 5 Department of Clinical Sciences, Orthopaedics, Lund University, Lund, Sweden
  6. 6 Department of Rheumatology, Tufts Medical Center, Boston, Massachusetts, United States
  7. 7 Department of Orthopaedics, Erasmus University Medical Center Rotterdam, Rotterdam, Zuid-Holland, Netherlands
  1. Correspondence to Jos Runhaar; j.runhaar{at}erasmusmc.nl

https://doi.org/10.1136/annrheumdis-2017-212276

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We appreciate the interest that Reginster and colleagues1 showed in our publication on subgroup effects of oral glucosamine for osteoarthritis (OA).2 We are pleased that the eLetter authors do not put forward any critique of our publication that requires our justification or clarification.

    As highlighted by the authors,1 the effectiveness of oral glucosamine products for knee and hip OA symptoms has been questioned. Nevertheless, due to the heterogeneous nature of the disease, whether certain subgroups of patients with OA could benefit from glucosamine has not been excluded. Since available randomised controlled trials are usually not powered to show subgroup effects, …

    View Full Text

    Footnotes

    • Handling editor Tore K Kvien

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    • Correction notice This article has been corrected since it published Online First. The third author’s name has been corrected to Marienke van Middelkoop.

    Linked Articles